Anavex Life Sciences Corp. (AVXL) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.81
↓-52% vs avg
5yr avg: 5.90
30Y Low3.7·High37.5
ROE
↓
-43.1%
-17% vs avg
5yr avg: -36.9%
30Y Low-186%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AVXL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Anavex Life Sciences Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $289M | $759M | $474M | $523M | $794M | $1.3B | $265M | $155M | $122M | $169M | $128M |
| Enterprise Value | $187M | $656M | $342M | $372M | $645M | $1.1B | $236M | $132M | $99M | $142M | $118M |
| P/E Ratio → | -5.78 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.81 | 8.00 | 3.94 | 3.68 | 5.57 | 8.31 | 9.72 | 7.62 | 5.95 | 6.97 | 20.23 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AVXL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AVXL Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -43.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | 4197.4% | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | 3838.7% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.1% | -43.1% | -32.8% | -33.4% | -32.7% | -42.6% | -110.6% | -129.0% | -78.0% | -88.1% | -154.2% |
| ROA | -38.7% | -38.7% | -29.7% | -30.9% | -30.5% | -38.7% | -87.8% | -105.8% | -66.9% | -72.1% | -118.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -47.8% | -47.8% | -40.3% | -39.2% | -34.8% | -47.1% | -130.8% | -141.0% | -85.8% | -101.7% | -163.1% |
AVXL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $103M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -1.10 | -1.06 | -1.05 | -1.01 | -1.07 | -1.09 | -1.12 | -1.13 | -1.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -57.84 | -53.84 | — | — | -190.24 | -620.01 | — | -1.38 |
Net cash position: cash ($103M) exceeds total debt ($0)
AVXL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Anavex Life Sciences Corp.'s current ratio of 11.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.32x to 11.60x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.60 | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.03 | 6.26 | 7.75 | 2.96 |
| Quick Ratio | 11.60 | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.55 | 6.26 | 7.75 | 2.96 |
| Cash Ratio | 11.47 | 11.47 | 8.64 | 12.05 | 14.60 | 14.09 | 4.00 | 4.40 | 5.90 | 7.66 | 2.88 |
| Asset Turnover | — | — | — | — | — | — | — | -0.03 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | -1408.18 | — | — | — |
AVXL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Anavex Life Sciences Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $85M | $83M | $80M | $77M | $70M | $58M | $49M | $45M | $41M | $35M |
Peer Comparison
Compare AVXL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AVXLYou | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 ATNM | $38M | -1.0 | — | — | — | — | -110.6% | — | — |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See AVXL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVXL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVXL vs SAVA
Side-by-side business, growth, and profitability comparison vs Cassava Sciences, Inc..
Start ComparisonAVXL — Frequently Asked Questions
Quick answers to the most common questions about buying AVXL stock.
What is Anavex Life Sciences Corp.'s P/E ratio?
Anavex Life Sciences Corp.'s current P/E ratio is -5.8x. This places it at the 50th percentile of its historical range.
What is Anavex Life Sciences Corp.'s ROE?
Anavex Life Sciences Corp.'s return on equity (ROE) is -43.1%. The historical average is -82.2%.
Is AVXL stock overvalued?
Based on historical data, Anavex Life Sciences Corp. is trading at a P/E of -5.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.